2Beneduce L, Castaldi F, Marino M, et al. Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes[ J]. Int J Biol Markers,2004,19(2) : 155-159.
4Lopez JB, Balasegaram M, Timor J, et al. Comparison of alphafetoprotein with some other tumour markers in Malaysians with hepatocellular carcinoma. Malays J Pathol, 1997,19:53-58.
5Beneduce L, Castaldi F, Marino M, et al. Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes. Int J Biol Markers, 2004,19 : 155-159.
6Sobin LH, Wittekind C. TNM classification of malignant tumours, 6th ed. New York:Wiley-Liss, 2002:81.
7Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology, 1983,148:839-843.
8Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti- HCV status. J Hepatol, 2001,34:570-575.
9Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet, 2003,362 : 1907-1917.
10El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med, 1999,340:745- 750.
3Bachtiar I,Santoso JM,Atmanegara B,et al. Combination of a-1 -acid glycoprotein and a-fetoprotein as an improved diagnostic tool forhepatocellular carcinoma[ J]. Clin Chim Acta,2009 ,399( 1-2) : 97-101.
4Kim KA,Lee EY,Kang JH,et al. Diagnostic accuracy of serumasiaio-al -acid glycoprotein concentration for the differential diagnosisof liver cirrhosis and hepatocellular carcinoma[ J]. Clin Chim Acta,2006,369(1) : 46-51.
5Le L, Chi K, Tyldesley S,et al. Identification of serum amyloid A asa biomarker to distinguish prostate cancer patients with bone lesions[JJ.Clin Chem, 2005, 51(4):695-707.
6Cho WC , Yip TT, Yip C , et al. Identification of serum amyloid Aprotein as a potential useful biomarker to monitor relapse of nasopha-ryngeal cancer by serum proteomic profiling [ J ]. Clin Cancer Res,2004,10(lPtl) :43-52.
